您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Carvedilol-d5
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Carvedilol-d5
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Carvedilol-d5图片
CAS NO:929106-58-1
包装与价格:
包装价格(元)
500 μg电议
1mg电议

产品介绍
An internal standard for the quantification of carvedilol
Cas No.929106-58-1
别名卡维地洛-D5,BM 14190-d5
Canonical SMILESCOC1=C(OCCNC([2H])([2H])C(C([2H])([2H])OC2=C(C(C=CC=C3)=C3N4)C4=CC=C2)([2H])O)C=CC=C1
分子式C24H21D5N2O4
分子量411.5
溶解度DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 5 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Carvedilol-d5is intended for use as an internal standard for the quantification of carvedilol by GC- or LC-MS. Carvedilol is a non-selective antagonist of the β-adrenergic receptor (β-AR; Kds = 1.78, 0.4, and 5.01 nM for β1-, β2-, and β3-ARs, respectively).1It also binds to α1-, but not α2-, adrenergic receptors (Kis = 0.81 and 3,400 nM, respectively).2Carvedilol reverses increases in heart rate induced by the β1-AR agonist isoproterenol in isolated guinea pig atria (Kb= 0.8 nM) and induces relaxation of isolated precontracted guinea pig trachea (Kb= 1.3 nM).3It prevents epinephrine-induced premature ventricular beats in a rat model of arrhythmia with an ED50value of 0.25 mg/kg.2Carvedilol also inhibits the contractile response to the α1-AR agonist norepinephrine in isolated rabbit aorta (Kb= 11 nM).3It decreases systolic blood pressure and heart rate in rat models of hypertension, including spontaneously hypertensive, renal hypertensive, and deoxycorticosterone acetate-treated rats when administered at doses ranging from 3 to 30 mg/kg.4Carvedilol also activates cardioprotective signaling through β-arrestin and ERK1/2 activation.5,6,7Formulations containing carvedilol have been used in the treatment of congestive heart failure and hypertension.

1.Baker, J.G.The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptorsBr. J. Pharmacol.144(3)317-322(2005) 2.Groszek, G., Nowak-KrÓl, A., Wdowik, T., et al.Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxy phenoxy)ethylamino)propan-2-ol analogs and its enantiomers. Part 2Eur. J. Med. Chem.44(12)5103-5111(2009) 3.Nichols, A.J., Sulpizio, A.C., Ashton, D.J., et al.In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilolPharmacology39(5)327-336(1989) 4.Tanaka, M., Masumura, H., Tanaka, S., et al.Studies on the antihypertensive properties of carvedilol, a compound with beta-blocking and vasodilating effectsJ. Cardiovasc. Pharmacol.10(Suppl 11)S52-S57(1987) 5.Wisler, J.W., DeWire, S.M., Whalen, E.J., et al.A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signalingProc. Natl. Acad. Sci. U.S.A.104(42)16657-16662(2007) 6.Kim, I.M., Tilley, D.G., Chen, J., et al.β-blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivationProc. Natl. Acad. Sci. U.S.A.105(38)14555-14560(2008) 7.Ibrahim, I.A.A.E.H., and Kurose, H.β-Arrestin-mediated signaling improves the efficacy of therapeuticsJ. Pharmacol. Sci.118(4)408-412(2012)